Work

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.506

Authors: Lisa A. Carey, William Thomas Barry, Brandy Pitcher, Katherine A. Hoadley, Maggie Chon U. Cheang, Carey K. Anders, N. Lynn Henry, Sara M. Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay Harris, Donald A. Berry, Charles M. Perou, Eric P. Winer, Clifford A. Hudis

Institutions: University of North Carolina at Chapel Hill, Dana-Farber Cancer Institute, Duke Medical Center, UNC Lineberger Comprehensive Cancer Center, University of Michigan, Memorial Sloan Kettering Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2241784931

Cites:

Cited by: 24

Related to: 10